![Naimish Patel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 928 942 $ al 31/07/2026
Naimish Patel is currently Chief Medical Officer at CRISPR Therapeutics AG since 2024.
Formerly, Dr. Patel was Global Head-Dupilumab Program at Sanofi.
Education includes a doctorate from McGill University and an undergraduate degree from Massachusetts Institute of Technology.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
CRISPR THERAPEUTICS AG 0,02 % | 29/05/2026 | 19.357 ( 0,02 % ) | 928 942 $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| CRISPR THERAPEUTICS AG | Director Técnico/Científico/I+D | 28/05/2024 |
| Empresas | Cargo | Fin |
|---|---|---|
| SANOFI | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
Sanofi
 Sanofi Pharmaceuticals: MajorHealth Technology Engages in research, development and production of pharmaceuticals & vaccines | Health Technology |
McGill University
 McGill University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
CRISPR Therapeutics AG
 CRISPR Therapeutics AG BiotechnologyHealth Technology Develops gene-based medicines | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
